RA Doesn’t Diminish Checkpoint Inhibitors’ Survival Benefit

MedPage Today) — People with rheumatoid arthritis (RA) and comorbid lung cancer showed almost the same overall survival as patients without RA when treated with pembrolizumab (Keytruda) or similar agents, a Medicare claims study indicated.
It…